<p>ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced the successful completion of enrollment of 104 patients in the Phase III clinical trial of IMM01 (Timdarpacept) for the first-line treatment of chronic myelomonocytic leukemia (CMML) as of December 31, 2025. The company expects to complete enrollment of the 132 patients required for interim analysis by the end of March 2026. Results from the trial have not yet been presented. IMM01 (Timdarpacept) in combination with azacitidine received orphan-drug designation from the U.S. Food and Drug Administration in November 2023. The company holds global intellectual property and commercial rights to IMM01 (Timdarpacept). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260121-11997345), on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment